June 9, 2021
FDA Approval of a New Treatment: What’s Next for the Alzheimer’s Community?
The Food and Drug Administration (FDA) has approved aducanumab as a new treatment for early-stage Alzheimer’s disease, and this AlzTalks explores what this means for the Alzheimer’s community.
Host Meryl Comer talked about the drug treatment with Biogen’s Samantha Budd Haeberlein, PhD, SVP, Head of Neurodegeneration Development and Karin Hellsvik, Head, External Communications and Patient Advocacy, and had a conversation about the decision with George Vradenburg, chairman and co-founder of UsAgainstAlzheimer’s; Russ Paulsen, UsA’s chief operating officer; and Jason Resendez, executive director of the UsAgainstAlzheimer’s Center for Brain Health Equity.
Meryl Comer also spoke about this new drug with advocates Jim and Geri Taylor. Geri, who lives with Alzheimer’s disease, participated in the clinical trial for this therapy.
Press the 'Play' button under the image at left to hear a podcast of the conversation, or watch the full session HERE.